Skitch Steven A, Valani Rahim
*Division of Emergency Medicine,McMaster University,Hamilton,ON.
CJEM. 2015 Nov;17(6):656-61. doi: 10.1017/cem.2015.56.
Diabetes is the most common pediatric endocrine disorder, and diabetic ketoacidosis (DKA) is the leading cause of diabetes-related morbidity and mortality. This article reviews pediatric DKA treatment protocols from across Canada and identifies similarities and differences.
Pediatric tertiary centres in Canada were asked for a copy of their DKA treatment protocol. For each protocol, we collected information on the amount of initial fluid bolus, maintenance fluid rate, insulin infusion rate, potassium replacement, monitoring and adjustment for serum glucose, administration of bicarbonate, and treatment for cerebral edema.
Responses were obtained from 13 sites. Treatment guidelines were consistent in their recommendations on timing and dosage of intravenous insulin, potassium replacement, monitoring and adjusting for serum glucose, and management of cerebral edema. Variability in treatment protocols was found chiefly in volume of initial fluid bolus (range: 5-20 mL/kg) and length of time boluses should be administered (20-120 min), maintenance fluid rates (based on weight or a 48-hr deficit), and the role of bicarbonate administration.
This is the first review of treatment protocols for pediatric DKA in Canada. It identified many common approaches but noted specific differences in fluid boluses, maintenance fluid rates, and bicarbonate administration. The extent of variation indicates the need for further study, as well as national guidelines that are evidence-based and consistent with best practices.
糖尿病是最常见的儿科内分泌疾病,而糖尿病酮症酸中毒(DKA)是糖尿病相关发病和死亡的主要原因。本文回顾了加拿大各地的儿科DKA治疗方案,并确定了异同点。
向加拿大的儿科三级中心索要其DKA治疗方案的副本。对于每个方案,我们收集了有关初始液体推注量、维持液速率、胰岛素输注速率、钾补充、血糖监测与调整、碳酸氢盐给药以及脑水肿治疗等方面的信息。
从13个机构获得了回复。治疗指南在静脉胰岛素的给药时间和剂量、钾补充、血糖监测与调整以及脑水肿管理的建议方面是一致的。治疗方案的差异主要体现在初始液体推注量(范围:5 - 20 mL/kg)、推注给药的时长(20 - 120分钟)、维持液速率(基于体重或48小时的液体缺失量)以及碳酸氢盐给药的作用上。
这是加拿大首次对儿科DKA治疗方案进行的综述。它确定了许多常见方法,但指出了在液体推注、维持液速率和碳酸氢盐给药方面的具体差异。差异程度表明需要进一步研究,以及制定基于证据且与最佳实践一致的国家指南。